Trinity Biotech Plc Share Price (NASDAQ: TRIB)

$1.52

▲

0.04

(2.7%)

Live

Last updated on August 28, 2025 at 11:36 pm IST

$₹

Check the interactive Trinity Biotech Plc Stock chart to analyse performance

Trinity Biotech Plc stock performance

as on August 28, 2025 at 11:36 pm IST

Today's Low:$1.51
Today's High:$1.53
$1.52
0.66%
Downside
Day's Volatility :1.31%
Upside
0.65%
52 Weeks Low:$1.44
52 Weeks High:$17.20
$1.52
5.26%
Downside
52 Weeks Volatility :91.63%
Upside
91.16%

Trinity Biotech Plc Stock Returns

Period	Trinity Biotech Plc	Index (Russel 2000)
3 Months	-53.75%	0.0%
6 Months	-60.69%	0.0%
1 Year	-86.36%	0.0%
3 Years	-95.55%	-6.9%

Trinity Biotech Plc Key Stats

Check Trinity Biotech Plc key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$1.48
Open	$1.455
Today's High	$1.57
Today's Low	$1.51
Market Capitalization	$27.4M
Today's Volume	$430.5K
52 Week High	$17.2
52 Week Low	$1.44
Revenue TTM	$61.6M
EBITDA	$-13.0M
Earnings Per Share (EPS)	$-9.0
Profit Margin	-51.64%
Quarterly Earnings Growth YOY	-0.77%
Return On Equity TTM	-1913.45%

Stock Returns calculator for Trinity Biotech Plc Stock including INR - Dollar returns

The Trinity Biotech Plc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Trinity Biotech Plc investment value today

Current value as on today

₹18,369

Returns

₹81,631

(-81.63%)

Returns from Trinity Biotech Plc Stock

₹85,991 (-85.99%)

Dollar Returns*

₹4,360 (+4.36%)

Indian investors sentiment towards Trinity Biotech Plc Stock

2180.0%

Period: Jul 28, 2025 to Aug 27, 2025. Change in 30 Days versus previous period

Investment in Trinity Biotech Plc Shares from India has grown by 2180.0% over the past 30 days, indicating increased transactional activity.

630%

Period: Jul 28, 2025 to Aug 27, 2025. Change in 30 Days versus previous period

Search interest for Trinity Biotech Plc Stock from India on INDmoney has increased by 630% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Trinity Biotech Plc

Name
Holdings %
Name
Holdings %
Perceptive Advisors LLC
1.92%
Hunter Associates Inc.
0.40%
Whitefort Capital Management, LP.
0.09%
Renaissance Technologies Corp
0.08%
HRT FINANCIAL LLC
0.07%
Citadel Advisors Llc
0.04%

Analyst Recommendation on Trinity Biotech Plc Stock

Rating

Trend

Buy

85%Buy

14%Hold

0%Sell

Based on 7 Wall street analysts offering stock ratings for Trinity Biotech Plc(by analysts ranked 0 to 5 stars)

Trinity Biotech Plc Share Price Target

What analysts predicted

Upside of 97.37%

Target:

$3.00

Current:

$1.52

Trinity Biotech Plc share price target is $3.00, a slight Upside of 97.37% compared to current price of $1.52 as per analysts' prediction.

Trinity Biotech Plc Stock Insights

Price Movement
In the last 7 days, TRIB stock has moved down by -81.0%
Increasing Revenue
Revenue is up for the last 2 quarters, 15.15M → 15.85M (in $), with an average increase of 4.5% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -4.75M → -16.95M (in $), with an average decrease of 256.3% per quarter
TRIB vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 33.1% return, outperforming this stock by 119.5%
TRIB vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 161.3% return, outperforming this stock by 256.8%
Price to Sales
ForTRIB every $1 of sales, investors are willing to pay $0.4, whereas for Boston Scientific Corp., the investors are paying $8.4 for every $1 of sales.

Trinity Biotech Plc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$90.4M	↓ 6.8%
Net Income	$-4.1M	↓ 270.13%
Net Profit Margin	-4.5%	↓ 6.96%

	FY20	Y/Y Change
Revenue	$102.0M	↑ 12.77%
Net Income	$-6.0M	↑ 47.88%
Net Profit Margin	-5.9%	↓ 1.4%

	FY21	Y/Y Change
Revenue	$93.0M	↓ 8.84%
Net Income	$875.0K	↓ 114.55%
Net Profit Margin	0.94%	↑ 6.84%

	FY22	Y/Y Change
Revenue	$74.8M	↓ 19.56%
Net Income	$-41.0M	↓ 4785.94%
Net Profit Margin	-54.83%	↓ 55.77%

	FY23	Y/Y Change
Revenue	$56.8M	↓ 24.0%
Net Income	$-24.0M	↓ 41.42%
Net Profit Margin	-42.26%	↑ 12.57%

	FY24	Y/Y Change
Revenue	$61.6M	↑ 8.31%
Net Income	$-31.8M	↑ 32.35%
Net Profit Margin	-51.64%	↓ 9.38%

Q3 FY23

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

	Q3 FY23	Q/Q Change
Revenue	$14.7M	↑ 5.61%
Net Income	$-6.7M	↑ 12.24%
Net Profit Margin	-45.79%	↓ 2.7%

	Q4 FY23	Q/Q Change
Revenue	$14.7M	↑ 0.18%
Net Income	$-3.3M	↓ 50.65%
Net Profit Margin	-22.56%	↑ 23.23%

	Q1 FY24	Q/Q Change
Revenue	$14.7M	↑ 0.0%
Net Income	$-3.3M	↑ 0.0%
Net Profit Margin	-22.56%	↑ 0.0%

	Q2 FY24	Q/Q Change
Revenue	$15.8M	↑ 7.75%
Net Income	$-6.8M	↑ 103.71%
Net Profit Margin	-42.65%	↓ 20.09%

	Q3 FY24	Q/Q Change
Revenue	$15.2M	↓ 4.36%
Net Income	$-4.8M	↓ 29.57%
Net Profit Margin	-31.41%	↑ 11.24%

	Q4 FY24	Q/Q Change
Revenue	$15.9M	↑ 4.65%
Net Income	$-17.0M	↑ 256.29%
Net Profit Margin	-106.93%	↓ 75.52%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$38.1M	↓ 8.03%

	FY20	Y/Y Change
Profit	$48.6M	↑ 27.44%

	FY21	Y/Y Change
Profit	$38.1M	↓ 21.62%

	FY22	Y/Y Change
Profit	$22.0M	↓ 42.1%

	FY23	Y/Y Change
Profit	$19.5M	↓ 11.78%

	FY24	Y/Y Change
Profit	$21.4M	↑ 10.24%

Q3 FY23

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

	Q3 FY23	Q/Q Change
Profit	$4.3M	↓ 14.91%

	Q4 FY23	Q/Q Change
Profit	$5.0M	↑ 16.71%

	Q1 FY24	Q/Q Change
Profit	$5.0M	↑ 0.0%

	Q2 FY24	Q/Q Change
Profit	$5.7M	↑ 14.79%

	Q3 FY24	Q/Q Change
Profit	$5.3M	↓ 7.43%

	Q4 FY24	Q/Q Change
Profit	$4.9M	↓ 8.12%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$5.5M	↓ 21.07%
Investing Cash Flow	$-15.4M	↓ 11.17%
Financing Cash Flow	$-4.0M	↓ 76.47%

	FY20	Y/Y Change
Operating Cash Flow	$23.8M	↑ 333.96%
Investing Cash Flow	$-10.2M	↓ 33.59%
Financing Cash Flow	$-2.7M	↓ 32.03%

	FY21	Y/Y Change
Operating Cash Flow	$13.2M	↓ 44.27%
Investing Cash Flow	$-8.7M	↓ 14.78%
Financing Cash Flow	$-6.0M	↑ 121.61%

	FY22	Y/Y Change
Operating Cash Flow	$-921.0K	↓ 106.96%
Investing Cash Flow	$-6.0M	↓ 31.23%
Financing Cash Flow	$-12.3M	↑ 104.72%

	FY23	Y/Y Change
Operating Cash Flow	$-11.6M	↑ 1154.83%
Investing Cash Flow	$24.8M	↓ 514.19%
Financing Cash Flow	$-16.0M	↑ 30.19%

	FY24	Y/Y Change
Operating Cash Flow	$-4.2M	↓ 63.74%
Investing Cash Flow	$-23.0M	↓ 192.78%
Financing Cash Flow	$28.8M	↓ 279.59%

Q3 FY23

Q1 FY24

Q3 FY24

Q4 FY24

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-4.7M	↑ 5.57%
Investing Cash Flow	$-886.0K	↓ 103.18%
Financing Cash Flow	$-2.4M	↓ 81.93%

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-4.8M	↑ 0.0%
Investing Cash Flow	$-14.0M	-
Financing Cash Flow	$20.9M	↑ 0.0%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-3.6M	↑ 229.45%
Investing Cash Flow	$-3.1M	-
Financing Cash Flow	$4.2M	↑ 8.38%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$3.4M	↓ 192.47%
Investing Cash Flow	$-2.7M	↓ 11.77%
Financing Cash Flow	$1.8M	↓ 57.45%

Trinity Biotech Plc Technicals Summary

Sell

Neutral

Buy

Trinity Biotech Plc is currently in a neutral trading position according to technical analysis indicators.

Trinity Biotech Plc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Trinity Biotech Plc	-55.82%	-60.69%	-86.36%	-95.55%	-96.93%
Medtronic Plc	-0.42%	1.44%	4.21%	3.53%	-14.35%
Edwards Lifesciences Corp.	0.53%	13.31%	17.84%	-10.47%	-5.75%
Boston Scientific Corp.	-0.56%	5.03%	33.14%	162.12%	158.09%
Stryker Corporation	-1.85%	1.09%	10.39%	90.11%	98.4%
Abbott Laboratories	2.7%	-3.25%	16.44%	29.08%	20.09%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Trinity Biotech Plc	0.56	NA	1.3	0.0	-19.13	-0.11	NA	-1.96
Medtronic Plc	25.61	25.61	2.16	5.46	0.1	0.04	0.03	37.46
Edwards Lifesciences Corp.	33.85	33.85	4.85	2.5	0.16	0.08	NA	17.94
Boston Scientific Corp.	63.33	63.33	1.85	2.98	0.12	0.05	NA	15.14
Stryker Corporation	52.37	52.37	2.24	13.49	0.14	0.08	0.01	55.43
Abbott Laboratories	16.55	16.55	4.17	5.14	0.31	0.07	0.02	29.05

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Trinity Biotech Plc	Buy	$27.4M	-96.93%	0.56	-51.64%
Medtronic Plc	Buy	$118.8B	-14.35%	25.61	13.63%
Edwards Lifesciences Corp.	Buy	$47.5B	-5.75%	33.85	72.96%
Boston Scientific Corp.	Buy	$157.6B	158.09%	63.33	13.55%
Stryker Corporation	Buy	$150.8B	98.4%	52.37	12.25%
Abbott Laboratories	Buy	$229.5B	20.09%	16.55	32.43%

About Trinity Biotech Plc

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. In addition, the company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

Organization	Trinity Biotech Plc
Employees	401
CEO	Mr. John Gillard
Industry	Health Technology

Key Management of Trinity Biotech Plc

Name	Title
Mr. John Gillard	President, CEO, Company Secretary & Director
Mr. Ronan O'Caoimh A.C.A.	Founder, Director & Executive Advisor
Dr. James Walsh Ph.D.	Executive Director of Business Development & Executive Director
Ms. Susan O'Connor	Interim Chief Financial Officer
Ms. Jacqueline O'Neill	Director of Operations
Ms. Louise Tallon	Chief Accounting Officer
Dr. Gary Keating Ph.D.	Chief Technology Officer
Ms. Eibhlin Kelly	Chief Information Officer
Mr. Colm Molloy	Group Director of Human Resources & Culture
Mr. Adrian Donohue	Chief Commercial Officer

Important FAQs about investing in TRIB Stock from India :

What is Trinity Biotech Plc share price today?

Trinity Biotech Plc share price today is $1.52 as on August 28, 2025 at 11:36 pm IST. Trinity Biotech Plc share today touched a day high of $1.53 and a low of $1.51.

What is the 52 week high and 52 week low for Trinity Biotech Plc share?

Trinity Biotech Plc share touched a 52 week high of $17.20 and a 52 week low of $1.44. Trinity Biotech Plc stock price today i.e. August 28, 2025 at 11:36 pm IST is trending at $1.52, lower by 91.16% versus the 52 week high.

How to invest in Trinity Biotech Plc Stock (TRIB) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Trinity Biotech Plc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Trinity Biotech Plc Shares that will get you 0.9868 shares as per Trinity Biotech Plc share price of $1.52 per share as on August 28, 2025 at 11:36 pm IST.

What is the minimum amount required to buy Trinity Biotech Plc Stock (TRIB) from India?

Indian investors can start investing in Trinity Biotech Plc (TRIB) shares with as little as ₹87.587 or $1 (as of August 28, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.87 in Trinity Biotech Plc stock (as per the Rupee-Dollar exchange rate as on August 28, 2025). Based on Trinity Biotech Plc share’s latest price of $1.52 as on August 28, 2025 at 11:36 pm IST, you will get 6.5789 shares of Trinity Biotech Plc. Learn more about fractional shares .

What are the returns that Trinity Biotech Plc has given to Indian investors in the last 5 years?

Trinity Biotech Plc stock has given -96.93% share price returns and 18.52% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?